Dallas, TX, Feb.  26, 2026  (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, &#34;The Oral Small-Molecule GLP-1 Race: Beyond

MDBH

PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

PatentVest Insight: Key Developments in GLP-1 Drug Market

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Dallas, TX, Feb.  26, 2026  (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, &amp;#34;The Oral Small-Molecule GLP-1 Race: Beyond</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>PatentVest released findings indicating a competitive race for oral GLP-1 drugs, essential for weight loss. With significant upcoming patent cliffs and the potential for market reconfiguration, MDBH&#039;s holdings in PatentVest emphasize its strategic positioning in intellectual property within this lucrative market.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>PatentVest&#039;s report highlights the race for oral small-molecule GLP-1 drugs.</li><li>GLP-1 drugs have a $71 billion market yet reach only 5% of patients.</li><li>Strong patent portfolios differentiate competitive drug programs in GLP-1 sector.</li><li>Upcoming patent cliffs for major drugs could reshape the market landscape.</li><li>MDB Capital Holdings owns PatentVest, integral to assessing IP strategy.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Eli Lilly (LLY)</strong>: Key player in GLP-1 space, impacts competitive landscape.</li><li><strong>Novo Nordisk (NVO)</strong>: Significant competitor; patent strategy critical for market retention.</li><li><strong>Pfizer (PFE)</strong>: Participating in GLP-1 race, could influence sector dynamics through alliances.</li><li><strong>AstraZeneca (AZN)</strong>: Committed to oral GLP-1 development; IP strategy will impact market access.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The article fits into Corporate Developments, highlighting critical insights into the competitive landscape for GLP-1 drugs and the role of PatentVest in evaluating these dynamics, directly influencing MDBH&#039;s strategic positioning in this market.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Discovery of key patents could lead to strategic partnerships boosting MDBH&#039;s valuation.</li><li>Emerging products with strong IP could capture significant market share pre-2031.</li><li>Investor sentiment may shift favorably amidst competitive highlights and market forecasts.</li><li>Projections of future revenue streams may enhance MDBH’s financial outlook and stock price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>GLP-1 market valued at $71 billion, covering less than 5% of eligible patients.</li><li>More than $47 billion in GLP-1-related deals since 2023.</li><li>Patent cliffs for semaglutide and tirzepatide expected in 2031 and 2036 respectively.</li><li>The report reviewed over 1,200 patent documents across 26 programs.</li><li>PatentVest is a subsidiary of MDB Capital Holdings.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider MDBH for potential upside driven by PatentVest&#039;s insights over the next 12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>Dallas, TX, Feb.  26, 2026  (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest <i>PatentVest Pulse</i> report, <b><i>"The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron."</i></b></p>  <p>As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remaining 95%. Clinical efficacy across leading programs is converging in the 12–16% weight-loss range.</p>  <p>In this increasingly competitive field, long-term differentiation depends not only on clinical performance but also on the strength and defensibility of each program's patent portfolio.</p>  <p>The report reviews more than 1,200 patent documents across 26 clinical-stage programs, mapping composition-of-matter claims, Markush scope, formulation layers, and method-of-use protection. The findings reveal dramatic disparities in patent depth between programs at similar development stages.</p>  <p>More than $47 billion in GLP-1-related deal value has been committed since 2023, yet most oral programs remain unpartnered. With semaglutide's patent cliff approaching in 2031 and tirzepatide's in 2036, long-term exclusivity will determine which assets become franchises and which face early generic pressure.</p>  <p>"When multiple drugs deliver similar weight-loss results, the competitive moat shifts beneath the surface," said Javier Chamorro, Chief Operating Officer of PatentVest. "The difference between a broad genus claim and a narrow composition patent can determine who owns this market for the next twenty years."</p>  <p>This analysis maps 50 oral small-molecule GLP-1 programs worldwide, including 30 in clinical development, and evaluates the IP positioning of leading assets from Eli Lilly, Novo Nordisk, Pfizer, Roche, AstraZeneca, Gilead, Structure Therapeutics, and others.</p>  <p>This is the first in a series of deep-dive analyses evaluating the structural and patent defensibility of each major program.</p>  <p>PatentVest, a division of MDB Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MDBH">MDBH</a>), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. Powered by a proprietary global IP database and a rigorous diligence methodology, PatentVest delivers actionable intelligence that reveals the structural advantages hidden beneath technology markets.</p>  <p>Read the full report here: <a href="https://www.globenewswire.com/Tracker?data=bUtKpFFbuLAB9OQoy6Xlg5jGoBNb8E-f1x_ArqiCiSeVjVCbTKMtI_P9D5lHvKs3Gvb4xJd0ymWdCvekizgeGJ1Kx2Fwd-Tz2SOLj12rJcRg6l0V9TwHUUW7M3IQUvMu20do0WyXoQ_768GDCIupLaKrzDNKjrAgqryg7BA_scp0upsKB6Yl6gmKL9Dpvuq2WDJohMncoMn2NOh1NUXrJyRvt2FdSH5JAktrHHeMLNJDiNzHfoa0tPhbj6vBijm1z3wkYiXR3odWpiK7L3upOoJbexrnMWpS7pkPxbuIUL-Piw4TD0R-TIwtqHHxeKLRX1Qk0uzspDq5Q1in27ZbP_w0T_-dor5lJkNjSJx3pN3LHF-fVFIgVmfUsgOMrm-T" rel="nofollow" target="_blank">https://insights.patentvest.com/https/www.patentvest.com/patentvest-pulse/the-oral-small-molecule-glp-1-race-beyond-orforglipron</a>.</p>  <p>For more information or inquiries, please contact <a href="https://www.globenewswire.com/Tracker?data=ZsuQdAurh_0O0ebql8-zusf1Lk-YRwsVUdS4lC8VfcIeziRjf0E52XuKhDVKOBzqMIgyyyT2tzjAaLZGUnd6vSocU_6vNXeCqgqdr29Hoirmn1ssGZ4rxN0C4XyqMxNgRiYRcLfFaa1SAPOtahz9DMQiRLMWhI0430S_GBsbjhIrAOL7N5O3hVuHWc9yvc4dFYt8xSZ8X7DoiQw4K5a3HQ-WBTGO1IAvPdmQg6u9wL-3EI1ycGbjkwoHLckkMg88lQEEmXNb7Y5jHIZPo4HHRTAi-lxOBzWaoHN9arJt3LBSbR5pcj034feY0pt5lbFxYoDzME7M7FB-V3UM7rNuPGDOQS3vlsB63YWM50DujTsU3D_o7M2DRjuftwlXGQYzDTdQZwW7c3yDVa1bRC4dh6FnZSw2TjKCGiCM7iEYD80cY26FXKlzD8TcHESDBLG71d6LtmMGgnXOQDkJsB5Dz2J75lVbhD2o8f2NpoN-OjfH1R5YUJP41xKEbZpoDl2y" rel="nofollow" target="_blank">info@patentvest.com</a>.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2MjMzMSM3NDU3ODg5IzUwMDEyNDY2Ng=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZDFkNzllMGQtMjMwZC00ZWU1LTgxZTgtYmJmY2NlNDA5NzRmLTUwMDEyNDY2Ni0yMDI2LTAyLTI2LWVu/tiny/PatentVest-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/600a6635-8e2f-41d9-b113-6139fe43166a"><img src="https://ml.globenewswire.com/media/600a6635-8e2f-41d9-b113-6139fe43166a/small/patentvest-logo97-copy-png.png" border="0" width="150" height="23" alt="Primary Logo"></img></a></p>

PatentVest released findings indicating a competitive race for oral GLP-1 drugs, essential for weight loss. With significant upcoming patent cliffs and the potential for market reconfiguration, MDBH's holdings in PatentVest emphasize its strategic positioning in intellectual property within this lucrative market.

PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News